Sunday, July 15, 2018 2:20:44 PM
Well, I saw it as a technical breakthrough. Leaving out the viral vector (as they did) would rule out the problem of immunogenicity*. But of course, their other major disadvantage remains (using a only much smaller, less patient-specific antigen pool, or even only a single one). So of course, I still see Oncosec as uniquely and much better positioned! :o)
dM
* By the way, this is also why I am sceptical of oncolytic virus-approaches. They might lose efficiency when recognized by the immune system in case of re-treatment and might become less efficient then, when used at a second or third time. Oncosec of course does not have a limit on re-treatment (which is one of the very important highlights, as so many trials show that IO treatments need to work over time).
Recent ONCSQ News
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/13/2024 07:30:19 PM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM
Element79 Gold Corp. Appoints Kevin Arias as Advisor to the Board of Directors, Strengthening Strategic Leadership • ELMGF • Sep 18, 2024 10:29 AM
Mawson Finland Limited Further Expands the Known Mineralized Zones at Rajapalot: Palokas step-out drills 7 metres @ 9.1 g/t gold & 706 ppm cobalt • MFL • Sep 17, 2024 9:02 AM
PickleJar Announces Integration With OptCulture to Deliver Holistic Fan Experiences at Venue Point of Sale • PKLE • Sep 17, 2024 8:00 AM